Pursuing next-gen precision neurotherapeutics and innovative early interventions
Transform the lives of patients with neurological conditions
Focused on novel, neuroprotective compounds that restore neuronal function, PurMinds develops innovative disease-modifying therapeutics for patients with neurological disorders. We leverage proven mechanisms of action and next-generation neuroplastogens to stimulate neuroplasticity, reduce neuro-inflammation, and promote neuro-rejuvenation.
In partnership with SpectroChip Technology, the world’s first-of-its-kind photonic chip-based point-of-care testing (POCT) technology, PurMinds is advancing the future of precision medicine through developing next-generation diagnostic solutions offering hospital-level accuracy, portability, universal LFIA compatibility, and cloud connectivity, aiming to identify diseases at their earliest and most treatable stages, especially for conditions affecting the central and peripheral nervous systems. By integrating biomarker intelligence and multi-omics data into portable point-of-care solutions, this data-driven approach transforms healthcare from reactive to proactive—supporting timely, personalized decisions that improve outcomes, reduce costs, and enhance quality of life for patients worldwide.
OUR MISSION is to transform the lives of patients with neurological conditions by pursuing next-generation precision neurotherapeutics and early intervention solutions. Our vision is to lead a new era in mental and neurological health by delivering breakthrough neurotherapeutics and transformative precision medicine solutions that restore hope, function, and quality of life for patients worldwide—while setting the global benchmark for innovation and integrity.
